H e m a t o lo g y E d u c a t io n - European Hematology Association

Borthakur G, et al. Cause of death in patients with lower-risk
myelodysplastic syndrome. Cancer. 2010 May 1;116(9):2174-9.
19. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald
A, Hellstrom-Lindberg E. Long-term outcome of treatment of
anemia in MDS with erythropoietin and G-CSF. Blood. 2005
Aug 1;106(3):803-11.
20. Jadersten M, Malcovati L, Dybedal I, Della Porta MG,
Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony
stimulating factor treatment associated with
improved survival in myelodysplastic syndrome. J Clin Oncol.
2008 Jul 20;26(21):3607-13.
21. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E,
et al. Lenalidomide in the myelodysplastic syndrome with chromosome
5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65.
22. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T,
Mead AJ, et al. Persistent malignant stem cells in del(5q)
myelodysplasia in remission. N Engl J Med. Sep 9;363(11):1025-37.
23. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD,
Cohn AL, et al. Hematologic response to three alternative dosing
schedules of azacitidine in patients with myelodysplastic
syndromes. J Clin Oncol. 2009 Apr 10;27(11):1850-6.
24. Silverman LR, McKenzie DR, Peterson BL, Holland JF,
Backstrom JT, Beach CL, et al. Further analysis of trials with
azacitidine in patients with myelodysplastic syndrome: studies
8421, 8921, and 9221 by the Cancer and Leukemia Group
B. J Clin Oncol. 2006 Aug 20;24(24):3895-903.
25. Silverman LR, Demakos EP, Peterson BL, Kornblith AB,
Holland JC, Odchimar-Reissig R, et al. Randomized controlled
trial of azacitidine in patients with the myelodysplastic syndrome:
a study of the cancer and leukemia group B. J Clin
Oncol. 2002;20(10):2429-40.
26. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D,
Faderl S, et al. Phase 1 study of low-dose prolonged exposure
schedules of the hypomethylating agent 5-aza-2’-deoxycytidine
(decitabine) in hematopoietic malignancies. Blood. 2004 Mar
1;103(5):1635-40.
27. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O’Brien S,
Cortes J, et al. Results of a randomized study of 3 schedules of
low-dose decitabine in higher-risk myelodysplastic syndrome
and chronic myelomonocytic leukemia. Blood. 2007 Jan
1;109(1):52-7.
28. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA,
Garcia-Manero G, et al. Multicenter Study of Decitabine
Administered Daily for 5 Days Every 4 Weeks to Adults With
Myelodysplastic Syndromes: The Alternative Dosing for
Outpatient Treatment (ADOPT) Trial. J Clin Oncol. 2009 Aug
10;27(23):3842-8.
29. WijerMans P, Suciu S, Baila L, Platzbecker U, Giagounidis A,
Selleslag D, et al. Low Dose Decitabine Versus Best
Supportive Care in Elderly Patients with Intermediate or High
Risk MDS Not Eligible for Intensive Chemotherapy: Final
Results of the Randomized Phase III Study (06011) of the
EORTC Leukemia and German MDS Study Groups Blood.
2008;112:226.
30. Neufeld EJ. Oral chelators deferasirox and deferiprone for
transfusional iron overload in thalassemia major: new data,
new questions. Blood. 2006 May 1;107(9):3436-41.
31. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro
CM, Deeg HJ, et al. Myelodysplastic syndromes. J Natl Compr
Canc Netw. 2011 Jan;9(1):30-56.
32. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic
syndromes: more than meets the eye? Blood. 2009 Dec
17;114(26):5251-5.
33. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada
K, Tomonaga M, et al. Retrospective nationwide survey of
Japanese patients with transfusion-dependent MDS and aplastic
anemia highlights the negative impact of iron overload on
morbidity/mortality. Eur J Haematol. 2007 Jun;78(6):487-94.
34. Rose C, Brechignac S, Vassilief D, Beyne-Rauzy O,
Stamatoullas A, Larbaa D, et al. Positive Impact of Iron
Chelation Therapy (CT) on Survival in Regularly Transfused
MDS Patients. A Prospective Analysis by the GFM. Blood.
2007;110:249.
35. Leitch HA. Improving clinical outcome in patients with
myelodysplastic syndrome and iron overload using iron chelation
therapy. Leukemia Research. 2007 Dec;31 Suppl 3:S7-9.
36. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et
al. Prognostic impact of elevated pretransplantation serum ferritin
in patients undergoing myeloablative stem cell transplantation.
Blood. 2007 May 15;109(10):4586-8.
37. Sanz G, Nomdedeu B, Such E, al. e. Independent Impact of
Iron Overload and Transfusion Dependency on Survival and
Leukemic Evolution in Patients with Myelodysplastic Syndrome.
Blood. 2008;112:640.
London, United Kingdom, June 9-12, 2011
38. Chan L, Gu L, Rauh M, Wells R. Iron Overload Accelerates
Development of Leukaemia: Evidence From a Mouse Model
Blood. 2010:abstract 122.
39. Young NS, Calado RT, Scheinberg P. Current concepts in the
pathophysiology and treatment of aplastic anemia. Blood.
2006 Oct 15;108(8):2509-19.
40. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS,
Barrett AJ. Antithymocyte globulin for patients with
myelodysplastic syndrome. British Journal of Haematology.
1997;99(3):699-705.
41. Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D,
Bacigalupo A, et al. Low IPSS score and bone marrow hypocellularity
in MDS patients predict hematological responses to
antithymocyte globulin. Leukemia. 2007 Jul;21(7):1436-41.
42. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang
X, et al. Phase II study of rabbit anti-thymocyte globulin,
cyclosporine and granulocyte colony-stimulating factor in
patients with aplastic anemia and myelodysplastic syndrome.
Leukemia. 2009 Jul;23(7):1297-302.
43. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett
AJ. A simple method to predict response to immunosuppressive
therapy in patients with myelodysplastic syndrome.
Blood. 2003 Oct 15;102(8):3025-7.
44. Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM,
Pfannes LV, et al. Altered naive and memory CD4+ T-cell
homeostasis and immunosenescence characterize younger
patients with myelodysplastic syndrome. Leukemia. 2009
Jul;23(7):1288-96.
45. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C,
Loeliger K, et al. Alemtuzumab treatment of intermediate-1
myelodysplasia patients is associated with sustained improvement
in blood counts and cytogenetic remissions. J Clin
Oncol. 2011 Dec 10;28(35):5166-73.
46. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein
C, Stadler M, et al. Immunosuppressive therapy for patients
with myelodysplastic syndrome: a prospective randomized
multicenter phase III trial comparing antithymocyte globulin
plus cyclosporine with best supportive care--SAKK 33/99. J
Clin Oncol. 2011 Jan 20;29(3):303-9.
47. Garcia-Manero G, Couriel D, Tambaro F, Gabrail N, Nadeem
A, Kadia T, et al. A Phase II Randomized Bayesian Study of
Very Low Dose Subcutaneous Decitabine Administered Daily
or Weekly Times Three in Patients with Lower Risk
Myelodysplastic Syndrome (MDS). Blood. 2009;114 119.
48. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma
S. A pilot pharmacokinetic study of oral azacitidine.
Leukemia. 2008 Sep;22(9):1680-4.
49. Garcia-Manero G, Gore S, Skikne B, Cogle C, Ning Y, MacBeth
K, et al. A Phase 1, Open-Label, Dose-Escalation Study to
Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics
of Oral Azacitidine in Patients with Myelodysplastic
Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
Blood. 2009;114:117.
50. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang
H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination
of 5-aza-2’-deoxycytidine with valproic acid in
patients with leukemia. Blood. 2006 Nov 15;108(10):3271-9.
51. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et
al. Safety and clinical activity of the combination of 5-azacytidine,
valproic acid, and all-trans retinoic acid in acute myeloid
leukemia and myelodysplastic syndrome. Blood. 2007 Oct
1;110(7):2302-8.
52. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al.
DNA methylation predicts survival and response to therapy in
patients with myelodysplastic syndromes. J Clin Oncol. 2010
Feb 1;28(4):605-13.
53. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer
S, et al. Clinical response and miR-29b predictive significance
in older AML patients treated with a 10-day schedule of
decitabine. Proceedings of the National Academy of Sciences
of the United States of America. 2010 Apr 20;107(16):7473-8.
54. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, et al.
Levels of miR-29b do not predict for response in patients with
acute myelogenous leukemia treated with the combination of
5-azacytidine, valproic acid, and ATRA. American journal of
hematology. 2011 Feb;86(2):237-8.
55. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H,
Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine
in mammalian DNA by MLL partner TET1.
Science. 2009 May 15;324(5929):930-5.
56. Itzykson R, Kosmider O, Cluzeau T, De Mas V, Dreyfus F,
Quesnel B, et al. Presence of TET2 Mutation Predicts A Higher
Response Rate to Azacitidine In MDS and AML Post MDS
Blood. 2010 December 4;116 (21):439.
Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 233 |